{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
icosapent ethyl
to a specific field?
Class (Stereo):
CHEMICAL (ACHIRAL)
Aloracetam [CAS 493] is a nootropic agent with potential in the treatment of Alzheimer's disease. Aloracetam was undergoing clinical evaluation with Hoechst for the treatment of Alzheimer's disease, but this research was discontinued later.
Status:
Investigational
Source:
INN:iminophenimide [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Iminophenimide is a piperazinedione derivative patented by American Cyanamid Co. as anticonvulsant.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Almurtide (CGP 11637) is a synthetic muramyl dipeptide (MDP) analogue with potential immunostimulating and antineoplastic activity. As a derivative of the mycobacterial cell wall component MDP, almurtide activates both monocytes and macrophages. This results in the secretion of cytokines and induces the recruitment and activation of other immune cells, which may result in indirect tumoricidal or cytostatic effects. CGP 11637 has been shown to prevent oncogenic viral infections in mice.
Status:
Investigational
Source:
NCT00267254: Phase 3 Interventional Completed Hyperlipidemia
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Torcetrapib is a CETP inhibitor which was developed by Pfizer for the treatment of diseases associated with elevated level of cholesterol. The drug was tested in phase III (in combination with atorvastatin) of clinical trials in coronary heart disease patients as well as in patients with hyperlipoproteinemia, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, however its development was terminated due to the high risk of death and heart problems.
Status:
Investigational
Source:
NCT01416389: Phase 2 Interventional Completed Metastatic Breast Cancer
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Litronesib is a specific, ATP-uncompetitive, allosteric, and potent small-molecule inhibitor of Eg5 with potential antineoplastic activity. Litronesib selectively inhibits the activity of Eg5, which may result in mitotic disruption, apoptosis and consequently cell death in tumor cells that are actively dividing. Histone-H3 phosphorylation of tumor and proliferating skin cells is a promising pharmacodynamic biomarker for in vivo anticancer activity of litronesib. Litronesib had been in phase I clinical trial for the treatment of solid tumors. The most frequent-related adverse events were hematologic such as neutropenia.
Class (Stereo):
CHEMICAL (ACHIRAL)
Nifursemizone, a 5-nitrofuran derivative, is an antiprotozoal drug. It is used in the treatment of histomoniasis in poultry.
Status:
Investigational
Source:
INN:metethoheptazine [INN]
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Metethoheptazine (WY-535) is an analgesic agent.
Status:
Investigational
Source:
INN:caloxetic acid [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Caloxetate Trisodium is triazaundecanedioic acid derivative patented by German pharmaceutical company as liver-specific magnetic resonance imaging contrast agent.
Status:
Investigational
Source:
INN:neocinchophen [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Neocinchophen is an analgesic and uricosuric. Cinchophen and neocinchophen (introduced by Chemische Fabrik auf Aktien as Atophan and Novatophan) were being advertised as superior substitutes for salicylates in the treatment of rheumatic fever. Chemically, cinchophen is phenylcinchoninic acid,
and neocinchophen is the ethyl ester of its methyl derivative.
Class (Stereo):
CHEMICAL (ABSOLUTE)
LANEPITANT is a selective nonpeptide antagonist for the neurokinin-1 receptor. It inhibits neurogenic dural inflammation. LANEPITANT was under development as a potential analgesic drug for the treatment of migraine, arthritis and diabetic neuropathy. However, it failed to show sufficient efficacy to support further development.
